OSSFF (Embla Medical hf) YoY EBITDA Growth: 21.93% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSSFF Embla Medical hf OSSFF
92 GF Score
Price $4.15
GF Value $5.15
! 1 Warning Sign
View Full Analysis

What is Embla Medical hf YoY EBITDA Growth?

Embla Medical hf OSSFF 92 YoY EBITDA Growth is 21.93% as of Jun. 2026. GuruFocus rates OSSFF with a GF Score™ of 92/100 and a GF Value™ of $5.15. The stock has 1 warning sign investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Embla Medical hf's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 21.93%.

Embla Medical hf's EBITDA per Share for the three months ended in Jun. 2026 was $0.14.

Embla Medical hf YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Embla Medical hf's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Embla Medical hf YoY EBITDA Growth Chart

Embla Medical hf Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 69.90 -20.29 22.58 16.37 10.55

Embla Medical hf Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.64 15.04 10.09 14.81 21.93
OSSFF
92GF Score
Embla Medical hf OSSFF
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Embla Medical hf YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Embla Medical hf's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(0.44-0.398)/ | 0.398 |
=10.55 %

Embla Medical hf's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(0.139-0.114)/ | 0.114 |
=21.93 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 21.93% mean?
Embla Medical hf (OSSFF) has a YoY EBITDA Growth of 21.93% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Embla Medical hf and its competitors.
Is Embla Medical hf's YoY EBITDA Growth too high?
Embla Medical hf's current YoY EBITDA Growth is 21.93%. Overall, Embla Medical hf has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does Embla Medical hf's YoY EBITDA Growth compare to ABT and SYK?
Embla Medical hf's YoY EBITDA Growth of 21.93% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Devices & Instruments company?
A good YoY EBITDA Growth depends on the Medical Devices & Instruments industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Embla Medical hf and its competitors. Embla Medical hf's current YoY EBITDA Growth is 21.93%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Embla Medical hf stock overvalued right now?
Embla Medical hf (OSSFF) has a current YoY EBITDA Growth of 21.93%. The stock's GF Value™ is $5.15, compared to a current price of $4.15 — trading 19.4% below its estimated fair value. The current YoY EBITDA Growth is 21.93%. Embla Medical hf's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Embla Medical hf (OSSFF), the current YoY EBITDA Growth is 21.93% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Embla Medical hf (OSSFF) Overvalued in 2026?

Based on GuruFocus' analysis, Embla Medical hf stock appears to be undervalued. The current stock price of $4.15 is trading 19.4% below its estimated GF Value™ of $5.15.

Key valuation signals for OSSFF:

  • YoY EBITDA Growth: 21.93%
  • GF Value™: $5.15 vs. price of $4.15 (19.4% below fair value)
  • GF Score™: 92/100 with 1 warning sign

No single metric tells the full story. See the OSSFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Embla Medical hf Business Description

Address Grjothals 5, Reykjavik, ISL
Embla Medical hf operates as an orthopedic products company specializing in the design, development, manufacturing and sales of prosthetics and bracing & supports products. The company also provides patient care through a network of Orthotic and Prosthetic (O&P) facilities. It sells its products in multiple countries, with Europe and North America representing its principal markets. The company operates within three business segments: Prosthetics & Neuro Orthotics, Bracing & Supports and Patient Care. The majority of the company's revenue is derived from the Prosthetics & Neuro Orthotics, which includes products designed for users with varying mobility needs, ranging from lower-activity applications to solutions intended for more active use.
92GF Score

Get the complete analysis for OSSFF

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.15
Price
$5.15
GF Value